Changes in Cerebral Glucose Metabolism After Electroconvulsive Therapy (ECT)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
There exist already a few studies that have measured changes of brain metabolism pre and post Electroconvulsive Therapy (ECT) by Positron emission tomography (PET) but these were all performed in a small number of patients and used different methodologies. It is therefore not surprising that these investigations provided inconsistent results, as reviewed previously {{23 Schmidt,E.Z. 2008}}.
In patients with treatment-refractory major depressive episodes, the investigators here therefore probed (a) whether changes in cerebral glucose metabolism measured by PET occur after treatment with ECT and (b) whether these correlate with the clinical amelioration of symptoms. To pursue this goal, the investigators assessed clinical effects, neurocognitive function, and brain metabolism using 18F-Fluoro-deoxyglucose (18F-FDG) PET at baseline and at the end of treatment.
Patients with a treatment refractory depression - defined as absent clinical improvement of depressive symptoms after at least two trials with antidepressants from different pharmacologic classes adequate in dose, duration of at least 6 weeks, and compliance {{30 Berlim,M.T. 2007}} - in whom ECT had been intended on clinical grounds were consecutively asked for participation in this study. Patients had to be between 18 and 80 years old and to be physically healthy.
| Condition | Intervention |
|---|---|
|
Major Depressive Disorder |
Device: Electroconvulsive therapy Device: 18-Fluoro-desoxy-glucose positron emission tomography |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Clinical Effects of Electroconvulsive Therapy in Severe Depression and Concomitant Changes in Cerebral Glucose Metabolism - an Exploratory Study |
- Brain glucose metabolism measured by FDG-PET [ Time Frame: one year ] [ Designated as safety issue: No ]
| Enrollment: | 13 |
| Study Start Date: | May 2006 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: ECT verum group
Patients with treatment refractory depression treated with ECT
|
Device: Electroconvulsive therapy
treatment for major depression
Other Name: no other names
Device: 18-Fluoro-desoxy-glucose positron emission tomography
intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min. It´s a neuroimaging technique. Other Name: no other names
|
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- clinical indication for ECT
- treatment refractory depressive episode
- age 18-85 y
Exclusion Criteria:
- addiction as a first diagnosis
- dementia
Contacts and Locations| Austria | |
| Medical University Graz; Department for Psychiatry | |
| Graz, Styria, Austria, 8036 | |
| Principal Investigator: | Bernd Reininghaus | Medical University of Graz |
More Information
Publications:
| Responsible Party: | Medical University of Graz |
| ClinicalTrials.gov Identifier: | NCT01514435 History of Changes |
| Other Study ID Numbers: | BRECT-2006-PET |
| Study First Received: | January 11, 2012 |
| Last Updated: | January 17, 2012 |
| Health Authority: | Austria: Ethikkommission |
Keywords provided by Medical University of Graz:
|
depression FDG-PET Electroconvulsive therapy glucose metabolism |
Additional relevant MeSH terms:
|
Depressive Disorder Depression Depressive Disorder, Major |
Mood Disorders Mental Disorders Behavioral Symptoms |
ClinicalTrials.gov processed this record on May 22, 2013